High-quality results. Delivered with confidence.
Seamless execution and high-quality results for your early clinical programs.
Dedicated to early clinical development, Quotient Sciences can help accelerate your molecule to your first-in-human and proof of concept milestones. We also offer a range of exploratory and regulatory-driven Phase 1 clinical pharmacology studies for registration and product labelling purposes.
We are focused on delivering the insight you need by offering end-to-end services to manage every aspect of your early clinical program. Our experience spans more than 30 years with more than 1,300 Phase I studies delivered at our clinical units in Miami and Nottingham.
1,300+ Phase 1 Studies
delivered across the last 30 years at our dedicated Phase I clinical units in Miami, FL and Nottingham, UK.
Database of 31,500+
active healthy volunteers, supported by dedicated recruitment and screening teams at each of our clinics. We also recruit a range of special populations and patient groups across all therapeutic areas.
99% of our studies
start on time, 98% enroll with full cohorts, and 99% of our subjects are retained throughout.
Explore our early clinical development services
Whether you are taking a new drug molecule into the clinic for the first time, or need to conduct exploratory and regulatory-driven Phase 1 clinical pharmacology studies such as DDI and human ADME— trust Quotient Sciences for the support needed to deliver your programs, safely and reliably.
First-in-human to proof-of-concept clinical studies
Quotient Sciences' first-in-human clinical studies are backed by extensive clinical and medical expertise, along with comprehensive formukation, manufacturing, and pharmacy capabilities.
Our fully integrated programs span all types of drug modalities and include single and multiple ascending dose (SAD/MAD) studies in healthy volunteers, special populations, and patient cohorts.
At our clinics in the US and UK, we have the ability to recruit patients across various therapeutic areas such as inflammation, metabolic diseases, and CNS disorders for initial proof-of-concept.
Exploratory and regulatory driven studies for registration and product labelling
Draw on our extensive clinical and medical expertise for your Phase 1 clinical pharmacology studies and product labeling purposes. Our capabilities include a range of study types, such as TQT, drug-drug interaction (DDI), food effect, bioavailability/bioequivalence (BA/BE), and human ADME studies.
Phase 1 clinical pharmacology studies can be executed standalone or bundled together for cost and time efficiencies. Additionally, we have the capacity to swiftly recruit large panels of healthy volunteers and special populations.
Purpose-built Phase I units, dedicated to the success and safety of your study.
Ensuring the safety of trial participants while mitigating risk is critical in clinical research.
Our purpose-built Phase I units in Miami, FL and Nottingham, UK are FDA- and MHRA-inspected, with trained staff to ensure the success and safety of your clinical program.
We provide 24/7 resident medical cover on a risk-assessed basis, and both clinical units are located in close proximity to University Hospital Emergency Departments. Additionally, our Nottingham unit has supplementary Phase I accreditation—the highest safety rating for the conduct of higher risk studies in the UK.
With a high number of experienced full-time physicians and an extended clinical team of licensed personnel, nurses, and technicians, we keep volunteer safety as our focus.
Our Miami, FL, USA Phase 1 Clinical Research Site
- 144-bed clinical unit
- FDA approved
- Database of more than 25,000 active healthy volunteers
- Ability to recruit select patient populations
- On-site compounding pharmacy with clean room for sterile products (USP 795/797/800 compliant)
- All clinical staff are life support trained as a minimum, and licensed EMTs, nurses and physicians are Advanced Life Support (ALS) certified in accordance with local guidelines
Our Nottingham, UK Phase 1 Clinical Research Site
- 85-bed clinical unit
- MHRA approved, including supplementary Phase 1 accreditation
- Database of more than 6,500 active healthy volunteers
- Ability to recruit select patient populations
- On-site GMP manufacturing
- All clinical staff are life support trained as a minimum, and all medical staff are Advance Life Support (ALS) certified in accordance with local guidelines
Meet Quotient Sciences Early Clinical Experts
Dr. Vanessa Zann
VP, Scientific Consulting, Translational Pharmaceutics & Clinical Pharmacology - USA
Dr. Vanessa Zann has over twenty-five years industry experience providing expert biopharmaceutic support to drug discovery, early ...
About VanessaHarpreet Smith, MBA, MSN, RN
VP and General Manager, Quotient Sciences - Miami
Harpreet Smith has been with SeaView Research and Quotient Sciences - Miami since 1999, where she has held various leadership role...
About HarpreetDr. Alyson Connor
Executive Director, Strategic Partnerships, Clinical Pharmacology
Dr. Alyson Connor has over 25 years of experience in the design and conduct of early-phase clinical programs, with emphasis on the...
About AlysonDr. Andrew Parker
Senior Drug Development Consultant
Dr. Andrew Parker has over two decades of experience in the pharmaceutical industry, spanning from preclinical development, throug...
About AndrewLearn about our reliable early clinical development and clinical pharmacology services.